Gene therapy of fibroproliferative vasculopathies

Current ideas in molecular mechanisms and biomedical technology

Amit K. Mitra, Devendra K. Agrawal

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Intimal hyperplasia occurs primarily as a part of the pathogenesis of coronary artery disease or secondary to therapeutic intervention in relieving vascular occlusion. Intimal hyperplasia involving vascular smooth muscle cells is found in atherosclerosis, post-balloon angioplasty restenosis, in-stent restenosis and vein graft disease, predominantly involving the use of saphenous vein conduits in coronary artery bypass grafting procedures. One potentially exciting area is that of gene therapy. Gene and protein expression patterns at the site of vasculoproliferative lesions have been widely studied and several target areas have been identified on the basis of whether the gene has an antiproliferative, proapoptotic, matrix degrading or endothelial protective action. Blood vessels are easily accessible for the delivery of the gene product, and experimental studies using animal models have used catheter-delivered gene products at the site of vascular injury. Currently, the application of antisense technology and adenoviral vector-mediated delivery has shown significant promise, albeit in in vitro or animal model settings. In this review, we discuss the current knowledge in the application of gene therapy in fibroproliferative vasculopathies. We examine some of the cellular mechanisms and intermediaries which could be potential candidates for gene targeting. We also present some of the advances in biomedical technology that might provide useful vehicles for pinpoint delivery of the gene product. Could the future of restenosis treatment be in gene therapy or is it misplaced enthusiasm.

Original languageEnglish
Pages (from-to)1185-1198
Number of pages14
JournalPharmacogenomics
Volume7
Issue number8
DOIs
StatePublished - Dec 2006

Fingerprint

Biomedical Technology
Genetic Therapy
Tunica Intima
Genes
Hyperplasia
Blood Vessels
Animal Models
Balloon Angioplasty
Gene Targeting
Vascular System Injuries
Saphenous Vein
Vascular Smooth Muscle
Coronary Artery Bypass
Smooth Muscle Myocytes
Stents
Coronary Artery Disease
Veins
Atherosclerosis
Catheters
Technology

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Genetics(clinical)

Cite this

Gene therapy of fibroproliferative vasculopathies : Current ideas in molecular mechanisms and biomedical technology. / Mitra, Amit K.; Agrawal, Devendra K.

In: Pharmacogenomics, Vol. 7, No. 8, 12.2006, p. 1185-1198.

Research output: Contribution to journalReview article

@article{2f9b581688aa4cec9a55e302e2045814,
title = "Gene therapy of fibroproliferative vasculopathies: Current ideas in molecular mechanisms and biomedical technology",
abstract = "Intimal hyperplasia occurs primarily as a part of the pathogenesis of coronary artery disease or secondary to therapeutic intervention in relieving vascular occlusion. Intimal hyperplasia involving vascular smooth muscle cells is found in atherosclerosis, post-balloon angioplasty restenosis, in-stent restenosis and vein graft disease, predominantly involving the use of saphenous vein conduits in coronary artery bypass grafting procedures. One potentially exciting area is that of gene therapy. Gene and protein expression patterns at the site of vasculoproliferative lesions have been widely studied and several target areas have been identified on the basis of whether the gene has an antiproliferative, proapoptotic, matrix degrading or endothelial protective action. Blood vessels are easily accessible for the delivery of the gene product, and experimental studies using animal models have used catheter-delivered gene products at the site of vascular injury. Currently, the application of antisense technology and adenoviral vector-mediated delivery has shown significant promise, albeit in in vitro or animal model settings. In this review, we discuss the current knowledge in the application of gene therapy in fibroproliferative vasculopathies. We examine some of the cellular mechanisms and intermediaries which could be potential candidates for gene targeting. We also present some of the advances in biomedical technology that might provide useful vehicles for pinpoint delivery of the gene product. Could the future of restenosis treatment be in gene therapy or is it misplaced enthusiasm.",
author = "Mitra, {Amit K.} and Agrawal, {Devendra K.}",
year = "2006",
month = "12",
doi = "10.2217/14622416.7.8.1185",
language = "English",
volume = "7",
pages = "1185--1198",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "8",

}

TY - JOUR

T1 - Gene therapy of fibroproliferative vasculopathies

T2 - Current ideas in molecular mechanisms and biomedical technology

AU - Mitra, Amit K.

AU - Agrawal, Devendra K.

PY - 2006/12

Y1 - 2006/12

N2 - Intimal hyperplasia occurs primarily as a part of the pathogenesis of coronary artery disease or secondary to therapeutic intervention in relieving vascular occlusion. Intimal hyperplasia involving vascular smooth muscle cells is found in atherosclerosis, post-balloon angioplasty restenosis, in-stent restenosis and vein graft disease, predominantly involving the use of saphenous vein conduits in coronary artery bypass grafting procedures. One potentially exciting area is that of gene therapy. Gene and protein expression patterns at the site of vasculoproliferative lesions have been widely studied and several target areas have been identified on the basis of whether the gene has an antiproliferative, proapoptotic, matrix degrading or endothelial protective action. Blood vessels are easily accessible for the delivery of the gene product, and experimental studies using animal models have used catheter-delivered gene products at the site of vascular injury. Currently, the application of antisense technology and adenoviral vector-mediated delivery has shown significant promise, albeit in in vitro or animal model settings. In this review, we discuss the current knowledge in the application of gene therapy in fibroproliferative vasculopathies. We examine some of the cellular mechanisms and intermediaries which could be potential candidates for gene targeting. We also present some of the advances in biomedical technology that might provide useful vehicles for pinpoint delivery of the gene product. Could the future of restenosis treatment be in gene therapy or is it misplaced enthusiasm.

AB - Intimal hyperplasia occurs primarily as a part of the pathogenesis of coronary artery disease or secondary to therapeutic intervention in relieving vascular occlusion. Intimal hyperplasia involving vascular smooth muscle cells is found in atherosclerosis, post-balloon angioplasty restenosis, in-stent restenosis and vein graft disease, predominantly involving the use of saphenous vein conduits in coronary artery bypass grafting procedures. One potentially exciting area is that of gene therapy. Gene and protein expression patterns at the site of vasculoproliferative lesions have been widely studied and several target areas have been identified on the basis of whether the gene has an antiproliferative, proapoptotic, matrix degrading or endothelial protective action. Blood vessels are easily accessible for the delivery of the gene product, and experimental studies using animal models have used catheter-delivered gene products at the site of vascular injury. Currently, the application of antisense technology and adenoviral vector-mediated delivery has shown significant promise, albeit in in vitro or animal model settings. In this review, we discuss the current knowledge in the application of gene therapy in fibroproliferative vasculopathies. We examine some of the cellular mechanisms and intermediaries which could be potential candidates for gene targeting. We also present some of the advances in biomedical technology that might provide useful vehicles for pinpoint delivery of the gene product. Could the future of restenosis treatment be in gene therapy or is it misplaced enthusiasm.

UR - http://www.scopus.com/inward/record.url?scp=33845866638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845866638&partnerID=8YFLogxK

U2 - 10.2217/14622416.7.8.1185

DO - 10.2217/14622416.7.8.1185

M3 - Review article

VL - 7

SP - 1185

EP - 1198

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 8

ER -